Strategies for mitigating an influenza pandemic

Development of strategies for mitigating the severity of a new influenza pandemic is now a top global public health priority. Influenza prevention and containment strategies can be considered under the broad categories of antiviral, vaccine and non-pharmaceutical (case isolation, household quarantine, school or workplace closure, restrictions on travel) measures. Mathematical models are powerful tools for exploring this complex landscape of intervention strategies and quantifying the potential costs and benefits of different options. Here we use a large-scale epidemic simulation to examine intervention options should initial containment of a novel influenza outbreak fail, using Great Britain and the United States as examples. We find that border restrictions and/or internal travel restrictions are unlikely to delay spread by more than 2–3 weeks unless more than 99% effective. School closure during the peak of a pandemic can reduce peak attack rates by up to 40%, but has little impact on overall attack rates, whereas case isolation or household quarantine could have a significant impact, if feasible. Treatment of clinical cases can reduce transmission, but only if antivirals are given within a day of symptoms starting. Given enough drugs for 50% of the population, household-based prophylaxis coupled with reactive school closure could reduce clinical attack rates by 40–50%. More widespread prophylaxis would be even more logistically challenging but might reduce attack rates by over 75%. Vaccine stockpiled in advance of a pandemic could significantly reduce attack rates even if of low efficacy. Estimates of policy effectiveness will change if the characteristics of a future pandemic strain differ substantially from those seen in past pandemics.

[1]  A. Langworthy,et al.  An influenza simulation model for immunization studies. , 1976, American journal of epidemiology.

[2]  T R Bender,et al.  An outbreak of influenza aboard a commercial airliner. , 1979, American journal of epidemiology.

[3]  I M Longini,et al.  Estimating household and community transmission parameters for influenza. , 1982, American journal of epidemiology.

[4]  L. A. Rvachev,et al.  A mathematical model for the global spread of influenza , 1985 .

[5]  I M Longini,et al.  Statistical inference for infectious diseases. Risk-specific household and community transmission parameters. , 1988, American journal of epidemiology.

[6]  R. May,et al.  Infectious Diseases of Humans: Dynamics and Control , 1991, Annals of Internal Medicine.

[7]  A. J. Hall Infectious diseases of humans: R. M. Anderson & R. M. May. Oxford etc.: Oxford University Press, 1991. viii + 757 pp. Price £50. ISBN 0-19-854599-1 , 1992 .

[8]  P. Kaye Infectious diseases of humans: Dynamics and control , 1993 .

[9]  P. Ward,et al.  Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. , 1999, JAMA.

[10]  HONG KONG INTERNATIONAL AIRPORT , 1999 .

[11]  O. Diekmann,et al.  Mathematical Epidemiology of Infectious Diseases: Model Building, Analysis and Interpretation , 2000 .

[12]  Christl A. Donnelly,et al.  Transmission intensity and impact of control policies on the foot and mouth epidemic in Great Britain , 2001, Nature.

[13]  S. Cornell,et al.  Dynamics of the 2001 UK Foot and Mouth Epidemic: Stochastic Dispersal in a Heterogeneous Landscape , 2001, Science.

[14]  R. Axtell Zipf Distribution of U.S. Firm Sizes , 2001, Science.

[15]  C. Fraser,et al.  Transmission Dynamics of the Etiological Agent of SARS in Hong Kong: Impact of Public Health Interventions , 2003, Science.

[16]  J. Robins,et al.  Transmission Dynamics and Control of Severe Acute Respiratory Syndrome , 2003, Science.

[17]  N. Ferguson,et al.  Planning for smallpox outbreaks , 2003, Nature.

[18]  Susan Mallett,et al.  A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. , 2003, The Journal of antimicrobial chemotherapy.

[19]  C. Fraser,et al.  Public Health Risk from the Avian H5N1 Influenza Epidemic , 2004, Science.

[20]  M. Cetron,et al.  Public Health Interventions and SARS Spread, 2003 David M. Bell* and World Health Organization Working Group on Prevention of International and Community Transmission of SARS1 , 2004 .

[21]  J. Oxford,et al.  The Great Influenza: The Epic Story of the Deadliest Plague in History , 2004 .

[22]  C. Viboud,et al.  A Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data , 2004, Statistics in medicine.

[23]  T. Geisel,et al.  Forecast and control of epidemics in a globalized world. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Y. Xia,et al.  Measles Metapopulation Dynamics: A Gravity Model for Epidemiological Coupling and Dynamics , 2004, The American Naturalist.

[25]  J. Robins,et al.  Transmissibility of 1918 pandemic influenza , 2004, Nature.

[26]  A. Nizam,et al.  Containing pandemic influenza with antiviral agents. , 2004, American journal of epidemiology.

[27]  A. Nizam,et al.  Containing Pandemic Influenza at the Source , 2005, Science.

[28]  Steve Leach,et al.  Potential Impact of Antiviral Drug Use during Influenza Pandemic , 2005, Emerging infectious diseases.

[29]  T. Tsang,et al.  Respiratory Infections during SARS Outbreak, Hong Kong, 2003 , 2005, Emerging infectious diseases.

[30]  Angus Nicoll,et al.  Avian influenza A (H5N1) infection in humans. , 2005, The New England journal of medicine.

[31]  S. Dowell,et al.  Human Disease from Influenza A (H5N1), Thailand, 2004 , 2005, Emerging infectious diseases.

[32]  Jeffery K. Taubenberger,et al.  Characterization of the 1918 influenza virus polymerase genes , 2005, Nature.

[33]  D. Cummings,et al.  Strategies for containing an emerging influenza pandemic in Southeast Asia , 2005, Nature.

[34]  J. Farrar,et al.  WRITING COMMITTEE OF THE WORLD HEALTH ORGANIZATION (WHO) CONSULTATION ON HUMAN INFLUENZA A/H5. AVIAN INFLUENZA A (H5N1) INFECTION IN HUMANS , 2005 .

[35]  UK stocks up on antiviral drug to tackle flu outbreak , 2005, BMJ : British Medical Journal.

[36]  Mark A. Miller,et al.  Synchrony, Waves, and Spatial Hierarchies in the Spread of Influenza , 2006, Science.

[37]  M Elizabeth Halloran,et al.  Design and evaluation of prophylactic interventions using infectious disease incidence data from close contact groups , 2006, Journal of the Royal Statistical Society. Series C, Applied statistics.

[38]  Keiji Fukuda,et al.  Nonpharmaceutical Interventions for Pandemic Influenza, International Measures , 2006, Emerging infectious diseases.

[39]  Krishna Rama-Murthy,et al.  Modeling of United States Airline Fares -- Using the Official Airline Guide (OAG) and Airline Origin and Destination Survey (DB1B) , 2006 .

[40]  P. Horby,et al.  Nonpharmaceutical Interventions for Pandemic Influenza, National and Community Measures , 2006, Emerging infectious diseases.

[41]  T. Geisel,et al.  The scaling laws of human travel , 2006, Nature.

[42]  P. M. Shearer,et al.  Zipf Distribution of U . S . Firm Sizes , 2022 .